BioAge Labs vs BioNTech
Side-by-side comparison of AI visibility scores, market position, and capabilities
Clinical-stage biotech targeting metabolic aging for obesity and muscle-wasting disorders. IPO Sep 2024 (Nasdaq: BIOA); $198M raised; lead program azelaprag discontinued; pivoting to NLRP3 inhibitors.
About
BioAge Labs is a clinical-stage biopharmaceutical company that harnesses the biology of human aging to discover novel targets and therapies for metabolic diseases. The company went public on the Nasdaq Global Select Market in September 2024 under the ticker BIOA, raising $198M. Its lead program, azelaprag — an oral APJ agonist — was discontinued in January 2025 after the Phase 2 STRIDES obesity trial observed liver transaminitis in a subset of patients. BioAge has since pivoted its APJ program to next-generation oral and parenteral agonists targeting 2026 IND submissions, while advancing BGE-102, a brain-penetrant NLRP3 inhibitor development candidate with potential best-in-class CNS and metabolic applications. The company continues to leverage its proprietary human aging database to identify and validate novel drug targets.
German mRNA pioneer co-developed COVID-19 vaccine with Pfizer; 20+ clinical programs in oncology and infectious disease;
About
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneered individualized neoantigen-specific immunotherapy and mRNA-based therapeutic approaches before co-developing the world's first authorized mRNA vaccine with Pfizer during the COVID-19 pandemic.\n\nBioNTech's pipeline spans over 20 clinical programs in oncology, infectious disease, and autoimmune conditions. Key assets include BNT111, an mRNA cancer vaccine for melanoma evaluated in combination with Regeneron's cemiplimab, as well as a suite of CAR-T, bispecific antibody, and mRNA-encoded cytokine programs. The company manufactures mRNA therapies at scale through its BioNTainer modular facilities deployable to emerging markets.\n\nBioNTech generated approximately €2.4 billion in revenue in 2024 and holds a robust cash position exceeding €17 billion, enabling sustained R&D investment. The company is recognized as one of the most pivotal biotech success stories of the 21st century, combining deep immunology science with scalable mRNA manufacturing to pursue a world where cancer is a manageable disease.
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.